Strategic Acquisition Eurofins acquisition of Transplant Genomics in June 2019 positions the company within a broader global testing network, enabling cross selling opportunities with Eurofins’ established lab capabilities and client base.

Noninvasive Monitoring Core offering TruGraf and OmniGraf provide noninvasive genomic-based monitoring for transplant patients, presenting a compelling value proposition for hospitals seeking to reduce invasive biopsies and improve post‑transplant outcomes.

Liver Focus Recent TruGraf Liver launch expands liver transplant screening and management capabilities, suggesting upsell potential to liver centers and transplant programs seeking immunosuppression optimization guidance.

Partnership Potential Historical partnerships with Viracor Eurofins and Quest for remote sample collection indicate appetite for collaboration; leverage for broader logistics, sample access, and integrated testing workflows.

Growth Signals Revenue in the mid tens of millions and a focused but small employee base imply high growth potential through scale advantages, cross‑selling within Eurofins, and expanded market reach in transplant diagnostics.